The Quantellect read.As of Nov 19, 2026, 9 active firms cover Haemonetics Corporation: 7 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $80.00 to $140.00, a moderate spread. The average target of $117.88 sits 4% below the current $122.83. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.58 next quarter toward $6.20 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Buy
Strong Buy00%
Buy778%
Neutral222%
Sell00%
Strong Sell00%
Based on 9 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$117.88
-4.0% downside
Average target across 8 active firms as of Nov 19, 2026 vs $122.83 current
Highest Target$140.00
Average Target$117.88
Lowest Target$80.00
Detailed analyst forecasts for HAE
Showing 1–10 of 10 named analysts shown · 9 active firms in the rating projection
As of Nov 19, 2026, 7 of 9 active firms rate HAE a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
HAE EPS & revenue forecast
EPS · NEXT QUARTER
$1.58
Range $1.49 – $1.66 · 12 analysts · +23% YoY
Next period, 12 analysts expect Haemonetics Corporation to earn $1.58 a share (range $1.49 – $1.66), versus $1.29 a year earlier. Full-year consensus is $5.34, growing to $6.20 the year after.
REVENUE · NEXT QUARTER
$388.0M
Range $378.1M – $395.1M · 12 analysts · +12% YoY
Revenue is expected to reach $388.0M (range $378.1M – $395.1M), +12.0% year-over-year. Full-year consensus is $1.4B, rising to $1.6B next year.
Top analysts covering Haemonetics Corporation
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HAE.
#1
Joanne Wuensch
Citigroup · Rank #35
Buy
$123.00+0.1% to target
Overall win rate
51%
+ Follow
#2
Anthony Petrone
Mizuho · Rank #121
Buy
$140.00+14.0% to target
Overall win rate
45%
+ Follow
#3
Mike Matson
Needham · Rank #285
Neutral
No targeton HAE
Overall win rate
36%
+ Follow
#4
Michael Petusky
Barrington Research · Rank #452
Buy
$140.00+14.0% to target
Overall win rate
32%
+ Follow
#5
Andrew Cooper
Raymond James · Rank #504
Buy
$125.00+1.8% to target
Overall win rate
25%
+ Follow
HAE stock forecast FAQ
What is HAE's average 12-month price target?+
The 8 active firms with a live target average $117.88 for Haemonetics Corporation over the next 12 months, ranging from a $140.00 high to a $80.00 low, as of Nov 19, 2026.
Is HAE stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 9 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for HAE?+
The Street-high target is $140.00 (Barrington Research), and the Street-low is $80.00 (B of A Securities). The average of all 8 active-firm targets is $117.88.
How many active Wall Street firms cover HAE?+
9 active firms have a recognized rating on Haemonetics Corporation as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering HAE?+
Among analysts who currently cover HAE, Joanne Wuensch of Citigroup has the strongest overall Quantellect track record (Rank #35). Their current call is Buy with a $123.00 target.
What is Haemonetics Corporation's projected EPS for next quarter?+
The consensus estimate is $1.58 per share (range $1.49 – $1.66) across 12 analysts. Full-year EPS is projected at $5.34, rising to $6.20 the following year.
How much revenue is Haemonetics Corporation expected to report next quarter?+
Consensus revenue is $388.0M (range $378.1M – $395.1M). Full-year revenue is projected at $1.4B, growing to $1.6B next year.
Have analysts been upgrading or downgrading HAE lately?+
As of Nov 19, 2026, 7 of 9 active firms rate HAE a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HAE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.